Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 174

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 174
---
ASED COMPENSATION

The Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was approved in 2021 (the “2021 Plan”). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based compensation. The 2021 Plan permits the Company’s board to change the type, terms and conditions of awards as circumstances may change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world events.

A summary of the stock option activity during the nine months ended September 30, 2024, is presented in the table below:

SCHEDULE OF STOCK OPTION ACTIVITY

|                                                      |     | Number of 
 options   |           |   |     | Weighted average 
 Exercise         
 price            |       |     | Remaining   
 contractual 
 life        
 (in years)  |     |     | Intrinsic value |        |
|:-----------------------------------------------------|:----|:----------|----------:|:--|:----|:-----------------|------:|:----|:------------|----:|:----|:----------------|-------:|
| Outstanding as of January 1, 2024                    |     |           | 2,050,197 |   |     | $                | 10.90 |     |             | 7.9 |     | $               | 36,363 |
| Granted                                              |     |           |   438,250 |   |     |                  |  1.93 |     |             | 9.4 |     |                 |      - |
| Forfeited and cancelled                              |     |           |      (625 | ) |     |                  |     - |     |             |   - |     |                 |      - |
| Outstanding as of September 30, 2024                 |     |           | 2,487,822 |   |     | $                |  9.20 |     |             | 7.5 |     | $               |      - |
| Exercisable as of September 30, 2024                 |     |           | 1,796,747 |   |     | $                | 11.80 |     |             | 7.0 |     | $               |      - |
| Vested and